• License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease
  • Agreement builds on Company's expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis
  • Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development